Bellevue Life Sciences Acquisition (BLAC) Competitors $1.45 -0.13 (-8.23%) As of 04/15/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock BLAC vs. FEMY, MDAI, COCH, CLGN, PTHL, PYPD, DRIO, NXL, RVP, and NXGLShould you be buying Bellevue Life Sciences Acquisition stock or one of its competitors? The main competitors of Bellevue Life Sciences Acquisition include Femasys (FEMY), Spectral AI (MDAI), Envoy Medical (COCH), CollPlant Biotechnologies (CLGN), Pheton Holdings Ltd Class A Ordinary Shares (PTHL), PolyPid (PYPD), DarioHealth (DRIO), Nexalin Technology (NXL), Retractable Technologies (RVP), and NEXGEL (NXGL). These companies are all part of the "medical equipment" industry. Bellevue Life Sciences Acquisition vs. Femasys Spectral AI Envoy Medical CollPlant Biotechnologies Pheton Holdings Ltd Class A Ordinary Shares PolyPid DarioHealth Nexalin Technology Retractable Technologies NEXGEL Femasys (NASDAQ:FEMY) and Bellevue Life Sciences Acquisition (NASDAQ:BLAC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, community ranking, analyst recommendations, institutional ownership and risk. Does the media prefer FEMY or BLAC? In the previous week, Femasys' average media sentiment score of 1.87 beat Bellevue Life Sciences Acquisition's score of 0.00 indicating that Femasys is being referred to more favorably in the media. Company Overall Sentiment Femasys Very Positive Bellevue Life Sciences Acquisition Neutral Which has preferable valuation and earnings, FEMY or BLAC? Bellevue Life Sciences Acquisition has lower revenue, but higher earnings than Femasys. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFemasys$1.63M18.00-$14.25M-$0.85-1.27Bellevue Life Sciences AcquisitionN/AN/AN/AN/AN/A Do institutionals and insiders hold more shares of FEMY or BLAC? 65.3% of Femasys shares are held by institutional investors. Comparatively, 55.3% of Bellevue Life Sciences Acquisition shares are held by institutional investors. 12.3% of Femasys shares are held by company insiders. Comparatively, 33.7% of Bellevue Life Sciences Acquisition shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community favor FEMY or BLAC? Femasys received 36 more outperform votes than Bellevue Life Sciences Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformFemasysOutperform Votes3675.00% Underperform Votes1225.00% Bellevue Life Sciences AcquisitionN/AN/A Do analysts rate FEMY or BLAC? Femasys presently has a consensus price target of $11.50, suggesting a potential upside of 964.81%. Given Femasys' stronger consensus rating and higher probable upside, equities research analysts plainly believe Femasys is more favorable than Bellevue Life Sciences Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Bellevue Life Sciences Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, FEMY or BLAC? Femasys has a beta of -2.55, indicating that its stock price is 355% less volatile than the S&P 500. Comparatively, Bellevue Life Sciences Acquisition has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500. Is FEMY or BLAC more profitable? Bellevue Life Sciences Acquisition has a net margin of 0.00% compared to Femasys' net margin of -1,435.77%. Bellevue Life Sciences Acquisition's return on equity of 0.00% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Femasys-1,435.77% -141.49% -82.30% Bellevue Life Sciences Acquisition N/A N/A N/A SummaryFemasys beats Bellevue Life Sciences Acquisition on 7 of the 12 factors compared between the two stocks. Remove Ads Get Bellevue Life Sciences Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for BLAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLAC vs. The Competition Export to ExcelMetricBellevue Life Sciences AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$5.86M$453.58M$1.99B$7.36BDividend YieldN/A8.21%2.80%4.32%P/E RatioN/A2.3622.5217.68Price / SalesN/A60.3357.5092.88Price / CashN/A69.0151.7234.64Price / BookN/A3.731.983.94Net IncomeN/A$35.22M-$333.48M$247.45M7 Day Performance-5.23%1.67%-0.03%0.48%1 Month Performance1.05%-0.39%-4.25%-7.08%1 Year Performance-86.45%19.95%3.56%-0.35% Bellevue Life Sciences Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLACBellevue Life Sciences AcquisitionN/A$1.45-8.2%N/A-86.5%$5.86MN/A0.00N/AGap DownHigh Trading VolumeFEMYFemasys2.474 of 5 stars$1.10-4.0%$11.50+941.7%-14.6%$29.73M$1.63M-1.3530Positive NewsMDAISpectral AI2.4858 of 5 stars$1.26+6.8%$4.75+277.0%-37.7%$29.29M$29.58M-1.9483Short Interest ↑COCHEnvoy Medical1.8903 of 5 stars$1.35+5.9%$9.00+569.1%-78.4%$28.69M$225,000.00-0.9534Gap DownCLGNCollPlant Biotechnologies2.3614 of 5 stars$2.44+1.5%$12.50+413.3%-52.6%$27.89M$515,000.00-1.5870PTHLPheton Holdings Ltd Class A Ordinary SharesN/A$3.65+0.6%N/AN/A$25.99M$448,196.000.0011News CoveragePositive NewsPYPDPolyPid2.9869 of 5 stars$2.44+1.5%$11.33+365.4%-40.0%$24.82MN/A-0.4980Analyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsDRIODarioHealth2.1161 of 5 stars$0.57-1.7%$1.50+164.1%-38.3%$23.90M$27.04M-0.61200News CoverageNXLNexalin Technology3.157 of 5 stars$1.58-4.5%$5.00+217.5%-12.6%$21.69M$168,721.00-2.553Gap DownRVPRetractable TechnologiesN/A$0.71+4.3%N/A-33.9%$21.23M$33.05M-1.31240Gap DownNXGLNEXGEL0.4822 of 5 stars$2.64+0.4%N/A+28.4%$20.21M$8.69M-4.5510Short Interest ↑Gap Down Remove Ads Related Companies and Tools Related Companies FEMY Competitors MDAI Competitors COCH Competitors CLGN Competitors PTHL Competitors PYPD Competitors DRIO Competitors NXL Competitors RVP Competitors NXGL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLAC) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellevue Life Sciences Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bellevue Life Sciences Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BLAC Stock Free BLAC Stock Alerts